# US 2006/0052334 A1 · Sequential therapy comprising a 20(S)-camptothecian and a pyrimidine base analog

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052334 A1
- Document ID: US20060052334A1
- Status: Published application
- Kind: A1
- Application number: 11/234,865
- Filed: 2005-09-23
- Published: 2006-03-09
- Earliest claimed: 2002-02-21
- Inventors: Joseph Rubinfeld; Karl Mettinger; John Lyons; Lawrence Romel
- Web page: https://patentgrep.com/patent/US20060052334A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.

## Claims

### Claim 1

A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising:
administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and
administering a pyrimidine base analog to the patient.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 1 day before the pyrimidine base analog is administered.

### Claim 3 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 2 days before the pyrimidine base analog is administered.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 3 days before the pyrimidine base analog is administered.

### Claim 5 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 4 days before the pyrimidine base analog is administered.

### Claim 6 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 5 days before the pyrimidine base analog is administered.

### Claim 7 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 1 and 90 days before the pyrimidine base analog is administered.

### Claim 8 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 2 and 90 days before the pyrimidine base analog is administered.

### Claim 9 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 3 and 90 days before the pyrimidine base analog is administered.

### Claim 10 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 4 and 90 days before the pyrimidine base analog is administered.

### Claim 11 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 5 and 90 days before the pyrimidine base analog is administered.

### Claim 12 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 1 day after the pyrimidine base analog is administered.

### Claim 13 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 2 days after the pyrimidine base analog is administered.

### Claim 14 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 3 days after the pyrimidine base analog is administered.

### Claim 15 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 4 days after the pyrimidine base analog is administered.

### Claim 16 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 5 days after the pyrimidine base analog is administered.

### Claim 17 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 1 and 90 days before or after the pyrimidine base analog is administered and is also administered within 1 day of when the pyrimidine base analog is administered.

### Claim 18 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 2 and 90 days before or after the pyrimidine base analog is administered and is also administered within 2 days of when the pyrimidine base analog is administered.

### Claim 19 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 3 and 90 days before or after the pyrimidine base analog is administered and is also administered within 3 days of when the pyrimidine base analog is administered.

### Claim 20 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is administered between 4 and 90 days before or after the pyrimidine base analog is administered and is also administered within 4 days of when the pyrimidine base analog is administered.

### Claim 21 (depends on 1)

A method according to claim 1 pancreatic cancer wherein the pyrimidine base analog is a fluorinated analog of a pyrimidine base.

### Claim 22 (depends on 1)

A method according to claim 1 pancreatic cancer wherein the pyrimidine base analog is a fluorinated analog of uracil.

### Claim 23 (depends on 1)

A method according to claim 1 wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.

### Claim 24 (depends on 1)

A method according to claim 1 wherein the disease associated with undesirable or uncontrolled cell proliferation is cancer.

### Claim 25 (depends on 1)

A method according to claim 1 wherein the cancer is selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostrate, and stomach cancer.

### Claim 26 (depends on 1)

A method according to claim 1 wherein the disease associated with undesirable or uncontrolled cell proliferation is pancreatic cancer.

### Claim 27

A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising:
administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not present in a pharmacologically active form in the patient's body; and administering a pyrimidine base analog to the patient.

### Claim 28 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 1 day before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 29 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 2 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 30 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 3 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 31 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 4 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 32 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 5 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 33 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 1 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 34 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 2 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 35 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 3 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 36 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 4 and 90 days before the period when the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 37 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 5 and 90 days before the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 38 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 1 day after the pharmacologically active pyrimidine base analog is no longer present in the patient's body.

### Claim 39 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 2 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.

### Claim 40 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 3 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.

### Claim 41 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 4 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.

### Claim 42 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered at least 5 days after the pharmacologically active pyrimidine base analog is no longer present in an active form in the patient's body.

### Claim 43 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 1 and 90 days before or after the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 1 day of when the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 44 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 2 and 90 days before or after the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 2 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 45 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 3 and 90 days before or after the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 3 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 46 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 4 and 90 days before or after the time when the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 4 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 47 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is administered between 5 and 90 days before or after the time when the pharmacologically active pyrimidine base analog is present in the patient's body and is also administered within 5 days of when the pharmacologically active pyrimidine base analog is present in the patient's body.

### Claim 48 (depends on 27)

A method according to claim 27 wherein the pyrimidine base analog is a fluorinated analog of a pyrimidine base.

### Claim 49 (depends on 27)

A method according to claim 27 wherein the pyrimidine base analog is a fluorinated analog of uracil.

### Claim 50 (depends on 27)

A method according to claim 27 wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.

### Claim 51 (depends on 27)

A method according to claim 27 wherein the disease associated with undesirable or uncontrolled cell proliferation is cancer.

### Claim 52 (depends on 27)

A method according to claim 27 wherein the cancer is selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myelorna, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostrate, and stomach cancer.

### Claim 53 (depends on 27)

A method according to claim 27 wherein the disease associated with undesirable or uncontrolled cell proliferation is pancreatic cancer.
